

23 December 2025

Section 708AA Cleansing Statement

This notice is given by Neurizon Therapeutics Limited ACN 094 006 023 (**ASX: NUZ**) (**Company**) under section 708AA(2)(f) of the *Corporations Act 2001* (Cth) (**Corporations Act**) as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84 and ASIC Corporations (Disregarding Technical Relief) Instrument 2016/73.

The Company has today announced that it intends to undertake a pro-rata non-renounceable entitlement offer to raise up to ~\$17.1m (before costs), under which eligible shareholders will be offered the opportunity to acquire 2 new fully paid ordinary shares in the Company (**Shares**) for every 5 Shares held as at 7.00pm on Tuesday, 30 December 2025 at an offer price of \$0.08 per new Share (**Entitlement Offer**).

Further details of the Entitlement Offer are contained in an information booklet that will be lodged with the ASX and made available to eligible shareholders on or around Monday, 5 January 2026.

The Company hereby confirms that:

- (a) the new Shares will be offered without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) the Company is providing this notice under paragraph (2)(f) of section 708AA of the Corporations Act;
- (c) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) sections 674 and 674A of the Corporations Act;
- (d) as at the date of this notice, there is no “excluded information” of the type referred to in sections 708AA(8) and 708AA(9) of the Corporations Act; and
- (e) the potential effect the Entitlement Offer will have on the control of the Company, and the consequences of that effect, will depend on a number of factors, including investor demand and existing shareholdings. Given the structure of the Entitlement Offer as a pro-rata issue and the current level of holdings of substantial holders, the Entitlement Offer is not expected to have any material effect or consequence on the control of the Company.

-Ends-

This announcement is authorised for release by the Board of Directors of Neurizon Therapeutics Limited.

For further information, please contact:

Dr. Michael Thurn

Managing Director and Chief Executive Officer
Neurizon Therapeutics Limited
enquiries@neurizon.com
+61 (3) 9692 7222

Lidija Damjanovic

Head of Marketing and Corporate Affairs
Neurizon Therapeutics Limited
lidija@neurizon.com
+61 (0) 425 700 504

Released through: Henry Jordan, Six Degrees Investor Relations, +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited